All data used in this study can be retrieved from the Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) databank under accession numbers, GSE62075 and GSE55983; and from the cBioportal web-based utility (<http://www.cbioportal.org>), at the following link: <http://bit.ly/2HAJyjG>.

Introduction {#sec001}
============

Uveal melanoma (UM) is the most common primary intraocular cancer in adults \[[@pone.0210276.ref001],[@pone.0210276.ref002]\]. The 5-year survival rate is between 50% and 70% and up to 50% of patients develop metastases within 36 months with a median survival of 6 months after metastasis occurrence \[[@pone.0210276.ref001],[@pone.0210276.ref002]\]. Unfavorable prognostic markers are the presence of epithelioid cells, large tumor diameter, anterior localization and chromosome 3 monosomy. Also, on the contrary to other cancers, the presence of tumor-infiltrating lymphocytes is associated to a poor outcome \[[@pone.0210276.ref003]--[@pone.0210276.ref005]\].

Recently, UMs have been classified as either Class 1 (with low metastatic risk) or Class 2 (with high metastatic risk), based on the transcriptomic profile of 12 genes. Class 1 UMs are further divided into Class 1a and Class 1b, the latter bearing a worse prognosis. Furthermore, the preferentially expressed antigen in melanoma (PRAME) gene has been reported to be an independent prognostic biomarker \[[@pone.0210276.ref006]\]. The liver accounts for 80--91% of the metastases. Although both cutaneous melanomas and UM originate from the melanocyte, their clinical behavior and underlying molecular mechanisms differ significantly \[[@pone.0210276.ref007]\]. For example, unlike cutaneous melanoma where metastasis to the central nervous system (CNS) occur in 40--60% of cases, only 4--15% of UM metastasize to CNS. The reasons for this discrepant metastatic pattern have so far not been dismantled.

The better understanding of biological differences and gene signatures between cutaneous and UM are clearly important to identify the factors that confer lower CNS metastatic potential to uveal vs. cutaneous melanoma.

Standard of care treatment of UM is represented by local radiation therapy, i.e. brachytherapy or charged-particle and proton-beam radiation, and enucleation for very large tumors \[[@pone.0210276.ref001],[@pone.0210276.ref002]\]. For metastatic UM, no FDA-approved standard of care is available \[[@pone.0210276.ref006]\]. While the development of immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), have dramatically increased the outcome for patients with advanced cutaneous melanoma, a comparable clinical benefit has not been observed for unresectable/metastatic UM. This can be partly explained by the observation that TILs from cutaneous melanoma have higher anti-tumor reactivity as compared to those from UM samples \[[@pone.0210276.ref008]\]. It is believed that since the eye is an immune privileged site, the tumor and its metastases show local immune-suppressive and immune-evasive features that affect the efficacy of current immunotherapies \[[@pone.0210276.ref009]--[@pone.0210276.ref012]\].

In the present study, we aimed to characterize the immunological features of primary UM cancer and to provide an association with prognostic markers and outcome. Also, we assessed the influence of the microenvironment on the expression of inhibitory immune checkpoints in UM. The results from this study may propel advances in the development of immune-based therapies for primary and recurrent UM cases.

Materials and methods {#sec002}
=====================

Immunological profiling of uveal melanoma {#sec003}
-----------------------------------------

In order to evaluate the immunological differences between UM and normal uveal melanocytes, the publicly available GSE62075 dataset was obtained from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>). GSE62075 included gene expression profiling of three primary cultures of human uveal melanocytes and of three human UM cell lines, the T115, T142 and T143 cells, at low culture passages (between 2 and 7). The G4851A SurePrint G3 Human GE 8x60 K array slide platform was used. Detailed description of the experimental design and procedures can be retrieved from the relative publication \[[@pone.0210276.ref013]\]. Data were analyzed using LIMMA (Linear Models for Microarray Analysis) and genes with a Benjamini & Hochberg false discovery rate\<0.05 were considered to be significant.

Immunological changes in uveal melanoma under inflammatory conditions {#sec004}
---------------------------------------------------------------------

To determine whether pro-inflammatory factors from activated T cells altered the immunological profiling of UM, the GSE55983 microarray dataset was used. GSE55983 included data from the three primary human UM cell lines, Mel290, Mel270 and 92.1. CD3+ T cells were isolated from whole blood of healthy donors, activated using anti-CD3/CD28 antibodies and cultured in 0.4 μm membrane inserts over UM cell lines, for 64 hours. After the incubation period, total RNA was collected from the UM cell lines and genome-wide transcriptomic expression was obtained using the Affymetrix Human Gene 1.0 ST microarray platform \[[@pone.0210276.ref014]\].

Identification of clinical predictors {#sec005}
-------------------------------------

Genes of interest included MHC Class I and Class II molecules, as well as inhibitory immune-checkpoints, i.e. PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47, CD155, GAL9, HVEM and CD200 \[[@pone.0210276.ref015]\]. In order to evaluate whether the expression levels of inhibitory immune-checkpoints and HLA genes in UM are able to predict prognosis or are associated to relevant clinical features, RNA Seq data from the TCGA datasets were downloaded through the cBioportal web-based utility ([http://www.cbioportal.org](http://www.cbioportal.org/); <http://bit.ly/2HAJyjG>). Data from 80 primary tumors, with no neoadjuvant therapy prior to excision were selected. Clinical data included metastasis free survival, overall survival, tumor diameters, BAP1 mutations and mitotic count.

Statistical analysis {#sec006}
--------------------

Gene expression differences between normal uveal melanocytes and UM were evaluated using unpaired two-tailed Student's t test. Enrichment of the "Immune Response" Biological Process (GO:0006955) among the significantly modulated genes in GSE62075 was calculated using an hypergeometric test. Paired two-tailed Student's t test was used to assess differences in gene expression in UM cells following pro-inflammatory stimulation. Statistical correlation between two continuous variables was calculated by partial correlation accounting for disease status, histological type, BAP1 mutation and adjuvant therapy. For each gene, predicted values were obtained by Multivariate General Linear Model using BAP1, Histological type and Adjuvant therapy as Fixed Factors and Mitotic count, Basal Diameter and Thickness as Covariates. Receiver Operating Characteristic (ROC) curves were constructed using disease status (recurrent disease) as nominal variable. Survival analysis was performed using Kaplan-Meier and its significance analyzed by log-rank (Mantel-Cox) test. Continuous variables were dichotomized using median value as cut off. For all the analysis, a p-value \<0.05 was considered statistical significant. Statistical analysis was performed with GraphPad Prism 5 (GraphPad Software, San Diego, C, US) and SPSS 24 (IBM SPSS Statistics, IBM Corporation, Armonk, NY, US).

Results {#sec007}
=======

Modulation of immune-related molecules in uveal melanoma {#sec008}
--------------------------------------------------------

Analysis of GSE62075 revealed that in UM, 417 genes are significantly modulated as compared to normal uveal melanocytes. Fifty-five genes resulted in common with genes belonging to the "Immune Response" Biological Process (GO:0006955), reaching a strong statistical significance (p\<0.001) ([Fig 1A](#pone.0210276.g001){ref-type="fig"}). Next, we wanted to compare the expression of MHC Class I and Class II molecules, as well as inhibitory immune-checkpoints, i.e. PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47, CD155, GAL9, HVEM and CD200, in UM in comparison to normal uveal melanocytes. MHC class I molecules resulted significantly downregulated in UM as compared to normal uveal melanocytes ([Fig 1B](#pone.0210276.g001){ref-type="fig"}), while no differences were observed for the MHC Class II genes, with the exception for HLA-DPA1 ([Fig 1C](#pone.0210276.g001){ref-type="fig"}). As regards the immune checkpoints investigated, no modulation was observed for PDL1, PDL2, B7-H3, B7-H4, TBFRSF6B, CD47, CD155, and GAL9 ([Fig 1D](#pone.0210276.g001){ref-type="fig"}). However, HVEM and CD200 were significantly downregulated in UM (p = 0.042 and p = 0.005).

![Immunological profiling of uveal melanoma.\
A. Venn diagram showing the number of significantly modulated genes in GSE62075 overlapping the "Immune response" genes (GO:0006955); B. MHC class I gene expression in uveal melanoma as determined in GSE62075; C. MHC class II gene expression in uveal melanoma as determined in GSE62075; D. Immune checkpoint gene expression in uveal melanoma as determined in GSE62075.](pone.0210276.g001){#pone.0210276.g001}

Inflammation drives immune escape in uveal melanoma {#sec009}
---------------------------------------------------

The GSE55983 microarray dataset was used to assess the modulation of the genes of interest upon inflammatory conditions. A trend of increase (p = 0.052) was observed for the MHC Class I molecules ([Fig 2](#pone.0210276.g002){ref-type="fig"}). Also, a significant upregulation in HLA-DOB and HLA-DPA1 was found (p\<0.05). A significant modulation was observed in PDL1 and PDL2 gene expression levels (p\<0.001), that were dramatically increased after incubation with activated T cell supernatant, as well as in CD47 levels (p\<0.05) ([Fig 3](#pone.0210276.g003){ref-type="fig"}). It is likely that the increase in expression of the above-mentioned genes are attributable to the effect of IFN-gamma secreted by activated T cells, as exposure of 92.1 cells to IFN-gamma (200 ng/ml) was associated to an upregulation of PDL-1, HLA-A, HLA-DOB and CD47 ([S1 Fig](#pone.0210276.s001){ref-type="supplementary-material"}).

![Inflammation drives immune escape in uveal melanoma.\
GSE55983 included data from the three primary human uveal melanoma cell lines, Mel290, Mel270 and 92.1. CD3+ T cells were isolated from whole blood from healthy donors, activated using anti-CD3/CD28 antibodies and cultured in 0.4 μm membrane inserts over uveal melanoma cell lines, for 64 hours. The expression levels of MHC Class I and II genes have been determined.](pone.0210276.g002){#pone.0210276.g002}

![Inflammation drives immune escape in uveal melanoma.\
GSE55983 included data from the three primary human uveal melanoma cell lines, Mel290, Mel270 and 92.1. CD3+ T cells were isolated from whole blood from healthy donors, activated using anti-CD3/CD28 antibodies and cultured in 0.4 μm membrane inserts over uveal melanoma cell lines, for 64 hours. The expression levels of immune-checkpoint genes have been determined.](pone.0210276.g003){#pone.0210276.g003}

To evaluate the association of the genes of interest with patients' and tumor characteristics, a partial correlation was performed to account for disease status, histological type and adjuvant therapy. As expected, OS and progression free survival (PFS) resulted significantly correlated ([Table 1](#pone.0210276.t001){ref-type="table"}). Also, a trend of correlation was observed between mitotic count and tumor diameters ([Table 1](#pone.0210276.t001){ref-type="table"}). PDL1 inversely correlated with OS, PFS and thickness of the tumor. Similarly, a significant inverse correlation was observed between HLA-A, HLA-B, HLA-H HLA-DPA and PFS ([Table 1](#pone.0210276.t001){ref-type="table"}). No assessment could be performed for B7-H4, whose expression levels were below detection sensitivity. A significant correlation was observed in the expression of all the Class I and Class II MHC molecules, as well as for MHC genes and PDL1 and PDL2 ([Table 2](#pone.0210276.t002){ref-type="table"}). Moreover, GAL9 significantly correlated with MHC class I and PDL1 expression ([Table 2](#pone.0210276.t002){ref-type="table"}). Finally, a significant correlation (p = 0.001) was observed between PDL1 and CD47 expression levels ([Table 2](#pone.0210276.t002){ref-type="table"}).

10.1371/journal.pone.0210276.t001

###### Correlation between gene levels and clinical variables as determined in the uveal melanoma samples from the TGCA cohort of patients.

Partial correlation was performed to account for clinical confounding variables.

![](pone.0210276.t001){#pone.0210276.t001g}

  Control Variables                                OS            PFS           MitoticCount   BasalDiameter   Thickness   HLAA        HLAB        HLAC        HLAF     HLAG     HLAH        HLADMA   HLADMB   HLADOA   HLADOB   HLADPA      HLADQA1   HLADQB1   HLADRA   PDL1        PDL2     B7H3     TNFRSF6B   GAL9     CD47     CD200    HVEM     CD155             
  ------------------------------------------------ ------------- ------------- -------------- --------------- ----------- ----------- ----------- ----------- -------- -------- ----------- -------- -------- -------- -------- ----------- --------- --------- -------- ----------- -------- -------- ---------- -------- -------- -------- -------- -------- -------- -------
  DiseaseStatus & HistoType & Adjuvant & BAP1MUT   OS            Correlation   1.000          0.983           0.014       0.127       0.243       -0.494      -0.352   -0.347   -0.239      -0.226   -0.458   -0.278   -0.291   -0.289      -0.192    -0.312    -0.309   -0.284      -0.281   -0.376   -0.170     0.038    -0.047   -0.107   -0.101   0.232    -0.105   0.112
  Significance (2-tailed)                                        **0.000**     0.935          0.441           0.136       **0.001**   **0.028**   **0.030**   0.143    0.166    **0.003**   0.086    0.072    0.074    0.241    0.053       0.056     0.080     0.083    **0.018**   0.301    0.820    0.776      0.518    0.540    0.155    0.523    0.498             
  PFS                                              Correlation   0.983         1.000          -0.006          0.123       0.254       -0.484      -0.364      -0.373   -0.254   -0.219      -0.453   -0.286   -0.306   -0.313   -0.192      -0.322    -0.301    -0.280   -0.294      -0.395   -0.171   0.040      -0.019   -0.111   -0.162   0.195    -0.119   0.092    
  Significance (2-tailed)                          **0.000**                   0.973          0.456           0.119       **0.002**   **0.023**   **0.019**   0.119    0.181    **0.004**   0.077    0.059    0.053    0.243    **0.046**   0.063     0.084     0.069    **0.013**   0.297    0.808    0.907      0.501    0.323    0.235    0.470    0.578             
  MitoticCount                                     Correlation   0.014         -0.006         1.000           0.287       0.292       -0.031      -0.036      -0.081   -0.107   0.057       0.038    0.037    -0.084   -0.111   -0.087      -0.027    0.069     0.015    -0.067      -0.196   -0.183   -0.036     -0.181   -0.014   -0.069   -0.107   -0.006   0.253    
  Significance (2-tailed)                          0.935         0.973                        0.077           0.071       0.852       0.830       0.622       0.517    0.731    0.817       0.821    0.611    0.503    0.597    0.872       0.675     0.930     0.685    0.231       0.266    0.827    0.270      0.934    0.677    0.518    0.972    0.120             
  BasalDiameter                                    Correlation   0.127         0.123          0.287           1.000       0.512       -0.127      -0.026      -0.149   -0.027   -0.055      -0.073   0.028    -0.034   -0.084   -0.025      -0.081    -0.015    -0.013   -0.047      -0.148   -0.068   0.024      0.225    0.171    -0.110   0.004    -0.090   0.316    
  Significance (2-tailed)                          0.441         0.456         0.077                          **0.001**   0.440       0.874       0.365       0.868    0.740    0.658       0.866    0.840    0.612    0.880    0.622       0.926     0.938     0.775    0.369       0.682    0.886    0.168      0.298    0.505    0.979    0.587    0.050             
  Thickness                                        Correlation   0.243         0.254          0.292           0.512       1.000       -0.137      -0.062      -0.114   -0.154   -0.153      -0.001   -0.074   -0.148   -0.187   -0.185      -0.120    -0.075    -0.124   -0.149      -0.367   -0.298   -0.089     0.078    0.184    -0.164   0.025    -0.047   0.204    
  Significance (2-tailed)                          0.136         0.119         0.071          **0.001**                   0.406       0.706       0.490       0.350    0.351    0.997       0.653    0.369    0.254    0.259    0.467       0.650     0.452     0.364    **0.021**   0.065    0.590    0.635      0.263    0.317    0.880    0.777    0.213             

10.1371/journal.pone.0210276.t002

###### Correlation between gene expression levels as determined in the uveal melanoma samples from the TGCA cohort of patients.

The Correlation Index (R^2^) is reported.

![](pone.0210276.t002){#pone.0210276.t002g}

             HLAA     HLAB     HLAC     HLAF     HLAG    HLAH     HLADMA   HLADMB   HLADOA   HLADOB   HLADPA   HLADQA1   HLADQB1   HLADRA   PDL1     PDL2     B7H3     TNFRSF6B   GAL9     CD47     CD200    HVEM     CD155
  ---------- -------- -------- -------- -------- ------- -------- -------- -------- -------- -------- -------- --------- --------- -------- -------- -------- -------- ---------- -------- -------- -------- -------- --------
  HLAA       1        0.81     0.807    0.685    0.286   0.962    0.717    0.651    0.717    0.468    0.755    0.67      0.603     0.687    0.572    0.51     0.284    0.1        0.317    -0.041   -0.156   0.368    -0.099
  HLAB       0.81     1        0.899    0.919    0.252   0.824    0.816    0.848    0.892    0.735    0.862    0.814     0.793     0.882    0.748    0.752    0.015    0.262      0.411    0.246    -0.119   0.133    -0.058
  HLAC       0.807    0.899    1        0.793    0.272   0.837    0.713    0.724    0.841    0.523    0.783    0.625     0.616     0.762    0.673    0.593    0.032    0.232      0.396    0.208    0.001    0.233    -0.099
  HLAF       0.685    0.919    0.793    1        0.195   0.665    0.84     0.936    0.933    0.909    0.891    0.845     0.892     0.962    0.701    0.887    -0.026   0.211      0.24     0.302    -0.051   0.044    -0.005
  HLAG       0.286    0.252    0.272    0.195    1       0.336    0.089    0.107    0.116    0.07     0.132    0.176     0.079     0.12     0.349    0.119    0.024    0.114      0.452    -0.06    0.065    0.019    0.3
  HLAH       0.962    0.824    0.837    0.665    0.336   1        0.723    0.621    0.704    0.418    0.745    0.655     0.573     0.665    0.562    0.447    0.283    0.124      0.424    -0.041   -0.157   0.375    -0.068
  HLADMA     0.717    0.816    0.713    0.84     0.089   0.723    1        0.916    0.907    0.77     0.936    0.908     0.902     0.921    0.561    0.759    0.289    -0.068     0.19     0.004    -0.267   0.262    0.006
  HLADMB     0.651    0.848    0.724    0.936    0.107   0.621    0.916    1        0.96     0.893    0.952    0.925     0.954     0.988    0.659    0.875    0.018    0.045      0.123    0.227    -0.13    0.084    -0.028
  HLADOA     0.717    0.892    0.841    0.933    0.116   0.704    0.907    0.96     1        0.803    0.957    0.859     0.884     0.973    0.697    0.814    0.053    0.027      0.142    0.234    -0.112   0.168    -0.074
  HLADOB     0.468    0.735    0.523    0.909    0.07    0.418    0.77     0.893    0.803    1        0.781    0.828     0.915     0.896    0.567    0.918    -0.035   0.121      0.083    0.29     -0.129   -0.099   0.022
  HLADPA     0.755    0.862    0.783    0.891    0.132   0.745    0.936    0.952    0.957    0.781    1        0.926     0.926     0.966    0.627    0.787    0.123    -0.003     0.175    0.112    -0.174   0.218    -0.066
  HLADQA1    0.67     0.814    0.625    0.845    0.176   0.655    0.908    0.925    0.859    0.828    0.926    1         0.963     0.92     0.625    0.812    0.101    -0.03      0.174    0.102    -0.218   0.085    0.025
  HLADQB1    0.603    0.793    0.616    0.892    0.079   0.573    0.902    0.954    0.884    0.915    0.926    0.963     1         0.954    0.57     0.86     0.054    0.027      0.115    0.165    -0.198   0.051    0.01
  HLADRA     0.687    0.882    0.762    0.962    0.12    0.665    0.921    0.988    0.973    0.896    0.966    0.92      0.954     1        0.667    0.878    0.033    0.051      0.145    0.224    -0.138   0.116    -0.025
  PDL1       0.572    0.748    0.673    0.701    0.349   0.562    0.561    0.659    0.697    0.567    0.627    0.625     0.57      0.667    1        0.732    -0.092   0.144      0.403    0.489    -0.084   -0.127   -0.099
  PDL2       0.51     0.752    0.593    0.887    0.119   0.447    0.759    0.875    0.814    0.918    0.787    0.812     0.86      0.878    0.732    1        -0.015   0.139      0.2      0.308    -0.146   -0.125   -0.067
  B7H3       0.284    0.015    0.032    -0.026   0.024   0.283    0.289    0.018    0.053    -0.035   0.123    0.101     0.054     0.033    -0.092   -0.015   1        -0.334     0.073    -0.563   -0.354   0.42     0.167
  TNFRSF6B   0.1      0.262    0.232    0.211    0.114   0.124    -0.068   0.045    0.027    0.121    -0.003   -0.03     0.027     0.051    0.144    0.139    -0.334   1          0.569    0.25     0.028    -0.184   -0.185
  GAL9       0.317    0.411    0.396    0.24     0.452   0.424    0.19     0.123    0.142    0.083    0.175    0.174     0.115     0.145    0.403    0.2      0.073    0.569      1        0.021    -0.107   -0.02    -0.046
  CD47       -0.041   0.246    0.208    0.302    -0.06   -0.041   0.004    0.227    0.234    0.29     0.112    0.102     0.165     0.224    0.489    0.308    -0.563   0.25       0.021    1        0.144    -0.353   -0.184
  CD200      -0.156   -0.119   0.001    -0.051   0.065   -0.157   -0.267   -0.13    -0.112   -0.129   -0.174   -0.218    -0.198    -0.138   -0.084   -0.146   -0.354   0.028      -0.107   0.144    1        -0.116   0.266
  HVEM       0.368    0.133    0.233    0.044    0.019   0.375    0.262    0.084    0.168    -0.099   0.218    0.085     0.051     0.116    -0.127   -0.125   0.42     -0.184     -0.02    -0.353   -0.116   1        -0.063
  CD155      -0.099   -0.058   -0.099   -0.005   0.3     -0.068   0.006    -0.028   -0.074   0.022    -0.066   0.025     0.01      -0.025   -0.099   -0.067   0.167    -0.185     -0.046   -0.184   0.266    -0.063   1

Receiver Operating Characteristic (ROC) curves were constructed using disease status (recurrent disease) as nominal variable. HLA-G resulted to be a significant predictor of recurrent disease, with an AUC of 0.810 (p = 0.05) ([Fig 4](#pone.0210276.g004){ref-type="fig"}; [Table 3](#pone.0210276.t003){ref-type="table"}). Among the immune-checkpoint genes, the best predictors found were CD47, with an AUC of 0.781 (p = 0.01); TNFRSF6B, with an AUC of 0.235 (p = 0.016); CD200 (AUC = 0.242; p = 0.018); HVEM (AUC = 0.163; p = 0.002); GAL9 (AUC = 0.284; p = 0.049)([Fig 4](#pone.0210276.g004){ref-type="fig"}; [Table 3](#pone.0210276.t003){ref-type="table"}). Accordingly to the ROC analysis, Kaplan-Meyer analysis revealed that higher levels of the MCH class I molecules---HLA-A, HLA-G, HLA-H---were associated to significantly lower disease-free survival time ([Table 4](#pone.0210276.t004){ref-type="table"}; [Fig 5](#pone.0210276.g005){ref-type="fig"}). Among the immune checkpoints, low levels of CD47 expression resulted in higher disease free survival, while higher expression of TNFRSF6B and GAL9 resulted in longer disease free survival ([Table 4](#pone.0210276.t004){ref-type="table"}; [Fig 5](#pone.0210276.g005){ref-type="fig"}).

![Receiver Operating Characteristic (ROC) curves were constructed for the genes of interest using disease status (recurrent disease) as nominal variable.\
Predicted values of the genes of interest were generated using General Linear Model to account for clinical confounding variables.](pone.0210276.g004){#pone.0210276.g004}

![For Kaplan-Meier analysis, predicted values of the genes of interest were generated using General Linear Model to account for clinical confounding variables and were dichotomized using median value as cut-off.\
For each gene, Log-rank (Mantel-Cox) analysis was performed to assess statistical differences in Progression-Free Survival time between patients with Low and High expression. Only graphs for significant data are shown.](pone.0210276.g005){#pone.0210276.g005}

10.1371/journal.pone.0210276.t003

###### Data from Receiver Operating Characteristic (ROC) curves generated for the genes of interest using disease status (recurrent disease) as nominal variable.

Predicted values of the genes of interest were generated using General Linear Model to account for clinical confounding variables.

![](pone.0210276.t003){#pone.0210276.t003g}

  Area Under the Curve                                           
  ------------------------------ ------ ------ ---------- ------ ------
  Predicted Value for HLAA       .667   .101   .128       .468   .865
  Predicted Value for HLAB       .585   .101   .438       .386   .784
  Predicted Value for HLAC       .542   .107   .698       .332   .753
  Predicted Value for HLAF       .533   .105   .765       .327   .739
  Predicted Value for HLAG       .810   .069   **.005**   .674   .947
  Predicted Value for HLAH       .706   .102   .060       .506   .906
  Predicted Value for HLADMA     .497   .105   .976       .292   .702
  Predicted Value for HLADMB     .408   .114   .403       .185   .632
  Predicted Value for HLADOA     .575   .098   .492       .382   .768
  Predicted Value for HLADOB     .369   .109   .232       .156   .582
  Predicted Value for HLADPA     .523   .104   .834       .319   .727
  Predicted Value for HLADQA1    .598   .104   .370       .395   .801
  Predicted Value for HLADQB1    .454   .108   .676       .243   .665
  Predicted Value for HLADRA     .487   .106   .905       .280   .694
  Predicted Value for PDL1       .572   .108   .511       .360   .784
  Predicted Value for PDL2       .382   .122   .282       .144   .621
  Predicted Value for B7H3       .320   .114   .101       .096   .545
  Predicted Value for B7H4       .644   .113   .189       .423   .865
  Predicted Value for TNFRSF6B   .235   .084   **.016**   .070   .401
  Predicted Value for GAL9       .284   .085   **.049**   .117   .452
  Predicted Value for CD47       .781   .102   **.010**   .580   .982
  Predicted Value for CD200      .242   .076   **.018**   .094   .390
  Predicted Value for HVEM       .163   .063   **.002**   .040   .287
  Predicted Value for CD155      .676   .112   .107       .457   .896

10.1371/journal.pone.0210276.t004

###### For Kaplan-Meier analysis, predicted values of the genes of interest were generated using General Linear Model to account for clinical confounding variables and were dichotomized using median value as cut-off.

For each gene, Log-rank (Mantel-Cox) analysis was performed to assess statistical differences in Progression-Free Survival time between patients with Low and High expression.

![](pone.0210276.t004){#pone.0210276.t004g}

                                        Estimate   Std. Error   95% Confidence Interval   Log Rank (Mantel-Cox)                 
  -------------------- ---------------- ---------- ------------ ------------------------- ----------------------- ------------- -----------------
  HLAA_predicted       Low expression   60.849     10.617       40.040                    81.658                  5.316044951   **0.021129918**
  High expression      33.412           4.032      25.509       41.315                                                          
  HLAB_predicted       Low expression   55.946     10.201       35.952                    75.939                  0.869944517   0.350970669
  High expression      37.788           3.113      31.685       43.890                                                          
  HLAC_predicted       Low expression   55.442     10.217       35.417                    75.468                  0.651291391   0.419651352
  High expression      37.976           2.947      32.201       43.751                                                          
  HLAF_predicted       Low expression   53.142     9.316        34.883                    71.400                  0.171876007   0.678449895
  High expression      36.567           2.563      31.544       41.589                                                          
  HLAG_predicted       Low expression   77.906     4.068        69.933                    85.880                  5.92839856    **0.014898775**
  High expression      36.197           4.697      26.991       45.403                                                          
  HLAH_predicted       Low expression   61.117     10.602       40.337                    81.897                  5.989849457   **0.01438843**
  High expression      32.887           4.265      24.528       41.246                                                          
  HLADMA_predicted     Low expression   52.667     9.338        34.365                    70.970                  0.082972562   0.773308785
  High expression      36.747           2.424      31.996       41.498                                                          
  HLADMB_predicted     Low expression   52.146     9.366        33.789                    70.503                  0.002775545   0.957984135
  High expression      37.265           2.248      32.858       41.672                                                          
  HLADOA_predicted     Low expression   55.442     10.217       35.417                    75.468                  0.651291391   0.419651352
  High expression      37.976           2.947      32.201       43.751                                                          
  HLADOB_predicted     Low expression   50.167     9.126        32.281                    68.054                  0.389689022   0.53246291
  high expression      39.300           1.184      36.979       41.621                                                          
  HLADPA_predicted     Low expression   54.889     10.239       34.820                    74.958                  0.470277913   0.492859343
  High expression      38.138           2.806      32.638       43.638                                                          
  HLADQA1_predicted    Low expression   57.875     10.408       37.476                    78.274                  2.255889815   0.133106926
  high expression      35.569           3.732      28.254       42.883                                                          
  HLADQB1_predicted    Low expression   52.947     9.253        34.811                    71.082                  0.132323225   0.716035297
  High expression      36.112           2.963      30.304       41.920                                                          
  HLADRA_predicted     Low expression   54.889     10.239       34.820                    74.958                  0.470277913   0.492859343
  High expression      38.138           2.806      32.638       43.638                                                          
  PDL1_predicted       Low expression   58.256     10.422       37.829                    78.684                  2.587052616   0.107740658
  High expression      35.469           3.734      28.150       42.788                                                          
  PDL2_predicted       Low expression   53.142     9.316        34.883                    71.400                  0.171876007   0.678449895
  High expression      36.567           2.563      31.544       41.589                                                          
  B7H3_predicted       Low expression   47.795     9.010        30.135                    65.454                  1.235888265   0.266264959
  High expression      43.523           1.969      39.663       47.383                                                          
  TNFRSF6B_predicted   Low expression   36.302     4.726        27.039                    45.564                  5.737360787   **0.016607729**
  High expression      77.909           4.072      69.927       85.892                                                          
  GAL9_predicted       Low expression   37.204     4.571        28.244                    46.164                  4.368411636   **0.036611103**
  High expression      75.214           6.375      62.719       87.709                                                          
  CD47_predicted       Low expression   63.613     10.808       42.430                    84.796                  9.483907795   **0.00207282**
  High expression      31.139           4.341      22.630       39.647                                                          
  HVEM_predicted       Low expression   46.037     8.365        29.642                    62.431                  2.86334347    0.090618963
  High expression      45.926           1.856      42.289       49.563                                                          
  CD155_predicted      Low expression   46.192     4.012        38.328                    54.056                  1.343753464   0.24637312
  High expression      47.095           10.294     26.920       67.271                                                          

Discussion {#sec010}
==========

Metastatic UM represents an unmet medical need characterized by extremely poor prognosis \[[@pone.0210276.ref001],[@pone.0210276.ref002]\]. Recently, gene expression and genomic analysis have identified different subsets of uveal cancer that could propel future efforts to design more individualized and effective treatment strategies \[[@pone.0210276.ref016]\]. The immune-based therapeutic strategies, that have increased the overall survival of cutaneous melanoma patients, have not yet led to significant improvement in unresectable/metastatic UM patients \[[@pone.0210276.ref017]\]. Nevertheless, the growing knowledge of cancer immunology suggests the possibility of novel therapeutic strategies.

In the present study, we wanted to formally characterize the transcriptomic features regulating the immunogenicity of UM and to determine whether T cell-mediated inflammation is able to affect the expression profile of genes putatively involved in immune-escape. In comparison to normal uveal melanocytes, significant lower levels of MHC genes were found in UM cells. Also, most of the inhibitory immune-checkpoints analyzed were not different in uveal cancer, with the exception of CD200 and HVEM, that resulted significantly reduced. Interestingly, the expression levels of several MHC class I and II molecules, as well as of PDL1 and PDL2 significantly increased under inflammatory conditions. It is reasonable that IFN-gamma may partly be responsible for the upregulation of these molecules, as in vitro treatment of the UM cell line, 92.1, with IFN-gamma, was associated to a significant increase in the expression of these genes ([S1 Fig](#pone.0210276.s001){ref-type="supplementary-material"}). Also, these observations are in line with previous reports by independent Authors who showed that IFN-gamma stimulation is able to affect the expression the localization of these molecule in UM, in turn resulting in an altered immune response of effector cells \[[@pone.0210276.ref009],[@pone.0210276.ref018],[@pone.0210276.ref019]\].

It is worth pointing out that our analysis of the TGCA data have been performed accounting for the presence of BAP1 mutation as confounding variable. Robertson et al. \[[@pone.0210276.ref020]\] have reported that UM with poor prognosis initially develops monosomy 3 (M3-UM), followed by BAP1 alterations that are associated with a unique global DNA methylation profile. They reported 4 transcription-based UM subsets, in which one cluster corresponded to M3-UM with immune infiltration. Also, They showed that a CD8 T cell infiltrate was present in 30% of M3-UM, while nearly absent in D3-UM, and interferon-gamma signaling (IFNG, IFNGR1, and IRF1), T cell invasion (CXCL9 and CXCL13), cytotoxicity (PRF1 and GZMA), and immunosuppression (IDO1, TIGIT, IL6, IL10, and FOXP3) were co-expressed with CD8a, suggesting that promotion of an immune environment plays a significant role in aggressive UM, i.e., M3 UM. Notably, no significant differences could be found in the expression of the genes here analyzed between BAP1 mutated and wild type samples (data not shown). In addition, we have provided data on the expression of the genes analyzed in our paper after stable loss of BAP1 in three UM cell lines. As it is shown in [S2 Fig](#pone.0210276.s002){ref-type="supplementary-material"}, the genes analyzed are not significantly modulated in the BAP1 deficient cell lines, with the exception of PDL-1 and HLA-A with resulted downregulated upon BAP1 loss (p = 0.022 and p = 0.031, respectively). Although these data may apparently contradict the negative prognostic value of BAP1 loss/mutation, however, they further support the important role of additional factors in the pathophysiological mechanisms underlying tumor growth, immune escape and prognosis in UM.

PDL1 inversely correlated with OS, PFS and thickness of the tumor. These findings have important clinical implications for the role of immunotherapies in the treatment of patients with UM. Unfortunately, to date, disappointing results have been obtained from Phase II clinical trials on unresectable/metastatic UM patients treated with the monoclonal antibodies targeting the PD1/PDL1 axis, pembrolizumab, nivolumab or atezolizumab \[[@pone.0210276.ref021]\]. These results are generally ascribed to the lack of expression of PDL1 in UM, as determined by independent Authors. Indeed, Javed et al. \[[@pone.0210276.ref022]\] have shown that only 5.1% of metastatic UM specimens expressed PDL1, while Kaunitz et al. \[[@pone.0210276.ref023]\] found that approximately 10% of UM expressed PDL1 and only correlated with a moderate--severe grade of CD8+ TILs. The data obtained from the TGCA database here analyzed confirm the low expression of PDL1, as the mean mRNA copy number was scarce (mean = 19.2; data not shown). However, the inverse correlation with the clinical data of the patients seem to point to an important role of this gene in UM. Additional markers of tumor immunogenicity and/or immune checkpoint molecules are needed, which may fine-tune the effector activity of tumor-infiltrating T cells and influence patients' prognosis. In fact, it is reasonable that functional redundancy occurs between alternative immune-inhibitory pathways and PDL1, so that combinatorial therapies may reshape the balance between activation and inhibitory signals received by immune infiltrating cells, thus restoring effective antitumor T-cell immunity.

It is also notable the inverse correlation between HLA Class 1 genes expression and patients' survival. This particular data fits in with the trend of increase in MHC expression that we observed under inflammatory conditions. Our data are in line with van Essen and collaborators (2016) showing that increased HLA class I levels are positively associated to a high infiltrate of CD3+, and CD68+ leukocytes. Accordingly, these Authors found that UM cells grafted in SCID-mice (lacking T and B cells) express the HLA class I and II genes at a much lower extent than their original counterpart \[[@pone.0210276.ref024]\]. Moreover, lack of HLA class I expression correlates with higher OS \[[@pone.0210276.ref025]\]. It is likely that this strategy may allow the tumor to escape the immune surveillance by NK cells \[[@pone.0210276.ref025]\], while the increase in PDL1 may block CTL response \[[@pone.0210276.ref025]\].

From the ROC and Kaplan-Meier analysis, a potential prognostic value for GAL9 and TNFRSF6B was also determined. However, the role of these genes in UM is still elusive. In fact, despite their immune-suppressive properties, we found that higher levels of expression are associated to better PFS. GAL9 encodes for a protein with affinity to bind β-galactoside and that possess carbohydrate recognition domains \[[@pone.0210276.ref026]\]. It was previously shown that GAL9, via interacting with TIM-3, is able to negatively regulate Th1 responses, to induce apoptosis of CTLs and to promote suppressive activity of Tregs. On the other hand, in a preclinical model of melanoma, GAL9 was found to expand plasmacytoid cell-like macrophages, thus increasing the NK-mediated cytolysis of cancer cells. Therefore, GAL9 may exert pleiotropic effects in cancer and the prognostic value of this gene in cancer remains controversial. In fact, a meta-analysis of fourteen studies, involving 2326 solid cancer patients, has recently revealed that high GAL9 expression was associated to improved overall survival, and was significantly correlated with smaller depth of invasion, earlier histopathological stage, negative lymph node metastasis and negative distal tumor metastasis \[[@pone.0210276.ref026]\].

TNFRSF6B is a member of the tumor necrosis factor receptor superfamily that acts as a decoy receptor for the apoptosis-inducing proteins Fas ligand (FasL), lymphotoxin analogues (LIGHT), and tumor necrosis factor-like ligand 1A (TL1A). In solid tumors, TNFRSF6B overexpression has been significantly associated with worse OS in patients with solid tumors, but its expression does not influence recurrence-free survival \[[@pone.0210276.ref027]\]. Additional functional data are needed to decipher the exact role of TNFRSF6B in regulating cancer recurrence, immune response to cancer and patients' survival in UM.

Finally, for the first time, we propose a possible role for CD47 in the immune evasive properties of UM. CD47 is a molecule with an immunoglobulin-like domain that is expressed on tumor cell surface and inhibits macrophage phagocytosis via binding the signal regulatory protein α (SIRPα) on phagocytes \[[@pone.0210276.ref028]\]. In gastric cancer, CD47 expression is an independent negative prognostic factor for gastric cancer, and in ovarian cancer, it is associated with adverse clinical characteristics and a poor prognosis \[[@pone.0210276.ref028]\]. We show here that CD47 is significantly upregulated by UM cells following inflammatory stimuli and that it represents a good independent predictor of disease progression. Anti-CD47-targeted therapy may represent a promising strategy to treat cancer and to improve long-term survival. A number of potent CD47 inhibitors are currently available (e.g. Hu5F9-G4, CC-90002, TTI-621, NI-1701, NI-1801, SRF231) and some of them are already under clinical investigation in human solid and hematological cancers \[[@pone.0210276.ref028]\].

Our *in silico* analysis highlights the complex pattern of gene expression that may orchestrate the interaction between UM cells and the immune cells and warrants further investigation aimed at exploring more focused pathogenic-tailored immunotherapeutic approaches in patients with UM.

Supporting information {#sec011}
======================

###### IFN-gamma drives immune escape in uveal melanoma.

The uveal melanoma 92.1 cells were exposed for 72 hrs to recIFN-gamma 200 ng/ml and the expression levels of the HLA-A, HLA-DOB, PDL-1 PDL-2 and CD47 genes were determined by Real-time PCR. Primer pairs sequences were obtained from the PrimerBank database. The data are presented as fold change increase with respect to unstimulated control cells and CI 95%. Statistical differences have been determined by two-tailed unparired Student's t test using the GrapPad Prism software.

(TIF)

###### 

Click here for additional data file.

###### BAP1 loss does not affect the expression of immune evading genes in uveal melanoma.

To determine whether stable loss of the BAP1 gene altered the immunological profiling of uveal melanoma, the GSE48863 microarray dataset was analyzed. GSE48863 included data from the three human uveal melanoma cell lines, 92.1, Mel290, and OCM1a, that were stably depleted using shRNA for either BAP1 or the control gene GFP. Cells were grown under puromycin selection for 4 weeks after lentiviral infection and microarray was performed using the Illumina HumanHT-12 V4.0 expression beadchip platform. Two biological replicates were performed for each cell line. An heatmap showing the expression levels of the genes of interest as fold change with respect to the relative control cells is presented. The heatmap is color coded from blue to red and the level of expression of each gene in the control cells is arbitrarily set to 1.

(TIF)

###### 

Click here for additional data file.
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